PE20090165A1 - PHARMACEUTICAL COMPOSITION BASED ON TELMISARTAN - Google Patents
PHARMACEUTICAL COMPOSITION BASED ON TELMISARTANInfo
- Publication number
- PE20090165A1 PE20090165A1 PE2008000465A PE2008000465A PE20090165A1 PE 20090165 A1 PE20090165 A1 PE 20090165A1 PE 2008000465 A PE2008000465 A PE 2008000465A PE 2008000465 A PE2008000465 A PE 2008000465A PE 20090165 A1 PE20090165 A1 PE 20090165A1
- Authority
- PE
- Peru
- Prior art keywords
- telmisartan
- pharmaceutical composition
- composition based
- disgregants
- methylbenzimidazole
- Prior art date
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title abstract 6
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title abstract 3
- 229960005187 telmisartan Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- -1 DISGREGANTS Substances 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
- 229910000000 metal hydroxide Inorganic materials 0.000 abstract 1
- 150000004692 metal hydroxides Chemical class 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UN COMPRIMIDO QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II EN FORMA AMORFA TAL COMO TELMISARTAN (ACIDO 4'-[2-n-PROPIL-4-METIL-6-(1-METILBENCIMIDAZOL-2-IL)-BENCIMIDAZOL-1-ILMETIL]-BIFENIL-2-CARBOXILICO), SORBITOL Y UN AGENTE BASICO TAL COMO HIDROXIDOS DE METAL ALCALINO, AMINOACIDOS BASICOS Y MEGLUMINA. EL TELMISARTAN ESTA PRESENTE EN UNA CANTIDAD DE ENTRE 10 MG Y 160 MG Y TIENE UN TAMANO DE PARTICULA MENOR DE 80 uM. DICHO COMPRIMIDO COMPRENDE EXCIPIENTES TALES COMO AGLUTINANTES, DISGREGANTES, SOLUBILIZANTES, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACIONREFERRING TO A TABLET CONTAINING AN ANTAGONIST OF THE AMORPHOUS ANGIOTENSIN II RECEPTOR SUCH AS TELMISARTAN (4 '- [2-n-PROPYL-4-METHYL-6- (1-METHYLBENZIMIDAZOLE-2-IL) -BENZIMIDAZOLE-1 -YLMETHYL] -BIPHENYL-2-CARBOXYL), SORBITOL AND A BASIC AGENT SUCH AS ALKALINE METAL HYDROXIDES, BASIC AMINO ACIDS AND MEGLUMINE. TELMISARTAN IS PRESENT IN A QUANTITY OF BETWEEN 10 MG AND 160 MG AND HAS A PARTICLE SIZE LESS THAN 80 uM. SAID TABLETS INCLUDES EXCIPIENTS SUCH AS BINDERS, DISGREGANTS, SOLUBILIZERS, AMONG OTHERS. IT IS ALSO REFERRED TO A PREPARATION PROCEDURE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104157A EP1970053A1 (en) | 2007-03-14 | 2007-03-14 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090165A1 true PE20090165A1 (en) | 2009-03-31 |
Family
ID=38179677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000465A PE20090165A1 (en) | 2007-03-14 | 2008-03-12 | PHARMACEUTICAL COMPOSITION BASED ON TELMISARTAN |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20100143465A1 (en) |
| EP (2) | EP1970053A1 (en) |
| JP (1) | JP5742045B2 (en) |
| KR (1) | KR101503674B1 (en) |
| CN (1) | CN101641084B (en) |
| AR (1) | AR065726A1 (en) |
| AT (1) | ATE493119T1 (en) |
| AU (1) | AU2008225754B2 (en) |
| BR (1) | BRPI0808797A2 (en) |
| CA (1) | CA2680608C (en) |
| CL (1) | CL2008000733A1 (en) |
| CO (1) | CO6220927A2 (en) |
| CY (1) | CY1111350T1 (en) |
| DE (1) | DE602008004217D1 (en) |
| DK (1) | DK2120884T3 (en) |
| EA (1) | EA018574B1 (en) |
| EC (1) | ECSP099629A (en) |
| ES (1) | ES2358770T3 (en) |
| HR (1) | HRP20110012T1 (en) |
| IL (1) | IL200125A (en) |
| MA (1) | MA31251B1 (en) |
| MX (1) | MX2009009201A (en) |
| MY (1) | MY145089A (en) |
| NZ (1) | NZ580185A (en) |
| PE (1) | PE20090165A1 (en) |
| PL (1) | PL2120884T3 (en) |
| PT (1) | PT2120884E (en) |
| RS (1) | RS51584B (en) |
| SI (1) | SI2120884T1 (en) |
| TN (1) | TN2009000371A1 (en) |
| TW (1) | TWI406678B (en) |
| UA (1) | UA96982C2 (en) |
| UY (1) | UY30961A1 (en) |
| WO (1) | WO2008110599A1 (en) |
| ZA (1) | ZA200905224B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| WO2009058950A2 (en) * | 2007-10-30 | 2009-05-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| WO2009135646A2 (en) | 2008-05-05 | 2009-11-12 | Farmaprojects, Sa | Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
| CZ301070B6 (en) * | 2008-07-31 | 2009-10-29 | Zentiva, A. S. | Telmisartan tablets |
| GB0822171D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Temisartan formulations |
| ES2598490T3 (en) | 2009-05-20 | 2017-01-27 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan drinkable pharmaceutical solution |
| EP2844067A4 (en) * | 2012-03-19 | 2015-11-25 | Althera Life Sciences Llc | ORAL COMPRESSOR FORMULATION COMPRISING ROSUVASTATIN WITH IMMEDIATE RELEASE AND EXTENDED RELEASE METFORMIN |
| JP6344678B2 (en) * | 2013-09-27 | 2018-06-20 | キョーリンリメディオ株式会社 | Telmisartan-containing preparation and method for producing the same |
| JP6096328B2 (en) * | 2014-02-10 | 2017-03-15 | 富士フイルム株式会社 | Orally disintegrating tablets |
| BE1021954B1 (en) * | 2014-06-05 | 2016-01-28 | Syral Belgium Nv | COMPOSITION OF SORBITOL WITH LOW FRIABILITY |
| FR3023128B1 (en) | 2014-07-01 | 2017-11-10 | Roquette Freres | NEW SWEETENING COMPOSITION |
| JP5871294B1 (en) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Immediate release oral tablets |
| KR20170001921A (en) | 2015-06-26 | 2017-01-05 | 대원제약주식회사 | A pharmaceutical composition comprising telmisartan with increased stability and a preparation method thereof |
| CN106420739A (en) * | 2016-10-31 | 2017-02-22 | 扬子江药业集团四川海蓉药业有限公司 | Telmisartan and amlodipine double-layer tablets and preparation method thereof |
| CN106800537B (en) * | 2017-01-18 | 2019-02-01 | 广东隆赋药业股份有限公司 | Butylphenyl phthaleine-Telmisartan heterocomplex and its preparation method and application |
| CN109316451B (en) * | 2017-07-31 | 2022-07-01 | 武汉朗来科技发展有限公司 | Oral solid preparation for treating hypertension and related diseases |
| SG11202010792TA (en) | 2018-05-02 | 2020-11-27 | Ferring Bv | Improved pharmaceutical formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3245170A1 (en) * | 1982-12-07 | 1984-06-07 | Merck Patent Gmbh, 6100 Darmstadt | IMPROVED SORBITE, METHOD FOR THE PRODUCTION AND USE |
| AU1042199A (en) * | 1998-11-06 | 2000-05-29 | Boehringer Ingelheim International Gmbh | Antihypertensive medicaments containing lacidipine and telmisartan |
| FR2787110B1 (en) * | 1998-12-11 | 2001-02-16 | Roquette Freres | SORBITOL PULVERULENT AND PROCESS FOR THE PREPARATION THEREOF |
| EA007614B1 (en) * | 2002-01-16 | 2006-12-29 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Bilayer pharmaceutical tablet and method for producing thereof |
| DE10244681A1 (en) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | New solid telmisartan-containing pharmaceutical formulations and their preparation |
| DE102004008804A1 (en) * | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Multilayer tablet |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| HRP20140212T1 (en) * | 2004-11-05 | 2014-04-11 | Boehringer Ingelheim International Gmbh | TWO-LAYER TABLET CONTAINING TELMISARTAN AND AMLODIPINE |
| JP2008524136A (en) * | 2004-12-17 | 2008-07-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy with telmisartan and hydrochlorothiazide |
| US20060159747A1 (en) * | 2004-12-17 | 2006-07-20 | Boehringer Ingelheim International Gmbh | Telmisartan and hydrochlorothiazide combination therapy |
-
2007
- 2007-03-14 EP EP07104157A patent/EP1970053A1/en not_active Ceased
-
2008
- 2008-03-12 PE PE2008000465A patent/PE20090165A1/en not_active Application Discontinuation
- 2008-03-12 CL CL200800733A patent/CL2008000733A1/en unknown
- 2008-03-13 EA EA200901169A patent/EA018574B1/en not_active IP Right Cessation
- 2008-03-13 BR BRPI0808797-0A patent/BRPI0808797A2/en not_active Application Discontinuation
- 2008-03-13 AR ARP080101038A patent/AR065726A1/en unknown
- 2008-03-13 JP JP2009553147A patent/JP5742045B2/en active Active
- 2008-03-13 MX MX2009009201A patent/MX2009009201A/en active IP Right Grant
- 2008-03-13 MY MYPI20093767A patent/MY145089A/en unknown
- 2008-03-13 AT AT08717753T patent/ATE493119T1/en active
- 2008-03-13 ES ES08717753T patent/ES2358770T3/en active Active
- 2008-03-13 PT PT08717753T patent/PT2120884E/en unknown
- 2008-03-13 SI SI200830179T patent/SI2120884T1/en unknown
- 2008-03-13 AU AU2008225754A patent/AU2008225754B2/en active Active
- 2008-03-13 WO PCT/EP2008/053009 patent/WO2008110599A1/en not_active Ceased
- 2008-03-13 NZ NZ580185A patent/NZ580185A/en unknown
- 2008-03-13 RS RS20110032A patent/RS51584B/en unknown
- 2008-03-13 DE DE602008004217T patent/DE602008004217D1/en active Active
- 2008-03-13 US US12/530,489 patent/US20100143465A1/en not_active Abandoned
- 2008-03-13 DK DK08717753.1T patent/DK2120884T3/en active
- 2008-03-13 EP EP08717753A patent/EP2120884B1/en not_active Revoked
- 2008-03-13 UA UAA200910184A patent/UA96982C2/en unknown
- 2008-03-13 TW TW097108903A patent/TWI406678B/en not_active IP Right Cessation
- 2008-03-13 KR KR1020097021453A patent/KR101503674B1/en not_active Ceased
- 2008-03-13 HR HR20110012T patent/HRP20110012T1/en unknown
- 2008-03-13 CN CN2008800075975A patent/CN101641084B/en active Active
- 2008-03-13 CA CA2680608A patent/CA2680608C/en not_active Expired - Fee Related
- 2008-03-13 UY UY30961A patent/UY30961A1/en not_active Application Discontinuation
- 2008-03-13 PL PL08717753T patent/PL2120884T3/en unknown
-
2009
- 2009-07-27 ZA ZA200905224A patent/ZA200905224B/en unknown
- 2009-07-28 IL IL200125A patent/IL200125A/en active IP Right Grant
- 2009-09-09 CO CO09096619A patent/CO6220927A2/en not_active Application Discontinuation
- 2009-09-11 MA MA32218A patent/MA31251B1/en unknown
- 2009-09-11 TN TNP2009000371A patent/TN2009000371A1/en unknown
- 2009-09-11 EC EC2009009629A patent/ECSP099629A/en unknown
-
2011
- 2011-03-22 CY CY20111100312T patent/CY1111350T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090165A1 (en) | PHARMACEUTICAL COMPOSITION BASED ON TELMISARTAN | |
| AR115939A2 (en) | COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE | |
| AR084620A1 (en) | A COMBINATION OF AN OPIACE AGONIST AND AN OPIACE ANTAGONIST IN THE TREATMENT OF PARKINSON'S DISEASE | |
| CO6440564A2 (en) | PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE | |
| ES2487271T3 (en) | DPP-IV inhibitor solid dosage formulations | |
| PA8849701A1 (en) | PHARMACEUTICAL DOSAGE FORM INCLUDING NIFEDIPINO OR NISOLDIPINO AND AN ANGLONENSIST OF ANGLOTENSIN II AND / OR A DIURETIC | |
| CL2009000598A1 (en) | Oral pharmaceutical composition comprising time-controlled pulsatile release particles (tpr), containing a weakly basic poorly soluble drug and an organic acid separated by a sustained release layer, and rapid release particles (rr); capsule comprising it; and its use to treat emesis. | |
| CL2013000677A1 (en) | Pharmaceutical composition in the form of tablets comprising gastrointestinal microgranules containing 100 to 800 mg of rifaximin, up to 30% w / w extragranular excipients and a film-forming coating; and use to treat an infectious and / or inflammatory bowel disease, such as crohn's disease. | |
| BR112012023324B8 (en) | process of preparing a fast-dissolving lyophilized multiphase dosage form | |
| BR112012024019A2 (en) | controlled release dosage form and method for releasing a drug | |
| CL2012000626A1 (en) | Sustained release oral pharmaceutical composition, comprising within a single dosage form, (i) a hydrophilic matrix, (ii) a therapeutically effective amount of a non-opioid amine-containing compound, (iii) a salt of an NSAID drug, and (iv) optionally an anionic surfactant. | |
| PE20142368A1 (en) | NOVEL AND POWERFUL TAPENTADOL DOSAGE FORMS | |
| CU24619B1 (en) | AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL FORMULATIONS THEREOF FOR ORAL ADMINISTRATION | |
| CO6400186A2 (en) | ULIPRISTAL ACETATE TABLETS | |
| MX349106B (en) | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin. | |
| MY147641A (en) | Fast release paracetamol tablets | |
| EA201400737A1 (en) | DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE | |
| ECSP11011289A (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
| GT201500035A (en) | ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS | |
| IN2015DN00637A (en) | ||
| TN2009000358A1 (en) | Pharmaceutical compositions comprising a calcilytic agent | |
| PT2389070E (en) | Disintegrable formulations of lanthanum carbonate | |
| AR086789A1 (en) | IBUPROFEN MASTICABLE TABLET | |
| CL2015003014A1 (en) | Pharmaceutical composition comprising 0.5-5 mg of (11?, 17?) - 17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one ; oral dosage form; use to treat and / or prevent a gynecological disease, such as fibroids in the uterus, endometriosis or excessive menstrual hemorrhages. | |
| CR20120617A (en) | COMBINATION OF XANTNA OXIDASA INHIBITORS AND ANTIGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |